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1. sUMMarY of perforMance of 
rapid diagnostic tests for Malaria: 
WHo prodUct testing roUnds 1–5 
1.1. introduction
WHO estimates that half the world’s population is at risk of 
malaria. In 2012, there were an estimated 207 million cases 
(with an uncertainty range of 135 million to 287 million) and 
an estimated 627 000 deaths (with an uncertainty range 
of 473 000 to 789 000). Approximately 90% of all malaria 
deaths occur in sub-Saharan Africa, and 77% occur in children 
under 5 years. Malaria remains endemic in 104 countries, and, 
while parasite-based diagnosis is increasing, most suspected 
cases of malaria are still not properly confirmed, resulting in 
over-use of antimalarial drugs and poor disease monitoring (1).
WHO recommends that malaria case management be based 
on parasite diagnosis in all cases (2). The use of antigen-
detecting rapid diagnostic tests (RDTs) is a vital part of this 
strategy, forming the basis for extending access to malaria 
diagnosis by providing parasite-based diagnosis in areas 
where good-quality microscopy cannot be maintained. The 
number of RDTs available and the scale of their use have 
increased rapidly over the past few years; however, limita-
tions of field trials and the heterogeneous nature of malaria 
transmission have limited the availability of the good-quality 
data on performance that national malaria programmes 
require to make informed decisions on procurement and 
implementation, and it is difficult to extrapolate the results 
of field trials to different populations and times. Therefore, 
in 2006, the WHO Special Programme for Research and 
Training in Tropical Diseases (TDR) and the Foundation for 
Innovative New Diagnostics (FIND) launched a programme 
to systematically evaluate and compare the performance of 
commercially available malaria RDTs. The results of WHO’s 
malaria RDT product testing have been published annually 
since 2009 and form the basis of the procurement criteria 
of WHO, other United Nations agencies, the Global Fund to 
Fight AIDS, Tuberculosis and Malaria, national governments 
and nongovernmental organizations. The data have guided 
procurement decisions, which, in turn, have shifted markets 
towards better-performing tests1 and are driving overall 
improvements in the quality of manufacturing. 
This summary presents an overview of the results of rounds 
1–5 of malaria RDT product testing and key concepts for 
understanding and using the results. It is published in 
conjunction with the release of the full report on round 5. 
The results of all rounds of testing should be considered as a 
single data set. The separate, full reports of each round (3–6) 
should be consulted for further details of methods, product 
performance and interpretation of the results.
1.2. the WHo product testing 
programme
The RDT evaluations summarized here were performed 
in collaboration by WHO, TDR, FIND, the United States 
Centers for Disease Control and Prevention (CDC) and other 
partners.1 All companies that manufacture according to the 
ISO 13485:2003 quality system standard were invited to 
submit one to three products for evaluation in the programme. 
In each round of testing, products are evaluated against 
geographically diverse, cryopreserved Plasmodium falci-
parum and P. vivax clinical samples diluted to 200 and 
2000 parasites/µL and with consistently comparable concen-
tration ranges of histidine-rich protein II (HRP2), Plasmodium 
lactate dehydrogenase (pLDH) and aldolase determined by 
quantitative enzyme-linked immunosorbent assay (ELISA) 
(Annex S1). In the first round of testing, 41 products from 
21 manufacturers were evaluated against prepared blood 
panels of cultured P. falciparum parasites, while 29, 50, 
48 and 42 products from 13, 23, 27 and 34 manufacturers 
were evaluated in rounds 2, 3, 4 and 5, respectively. Of these 
210 products, 206 progressed to testing against panels of 
patient-derived P. falciparum and P. vivax parasites and a 
parasite-negative panel. Thermal stability was assessed after 
2 months of storage at elevated temperature and humidity, 
and a descriptive assessment of ease of use was made. Many 
manufacturers have decided voluntarily to submit products 
to one or more rounds of testing, and, in round 5, a require-
ment was instituted to resubmit products for re-evaluation 
within 5 years of original testing (Table S1). Of the 206 fully 
evaluated products, 32 have been evaluated twice, 11 have 
been evaluated three times and two evaluated four times 
in rounds 1–5. Of the 147 unique products tested in the 
programme, 36 detect P. falciparum alone, 101 detect and 
differentiate P. falciparum from non-P. falciparum malaria 
(either pan-specific or species-specific for P. vivax or P. vivax, 
ovale and malariae), 9 detect P. falciparum and non-P. falci-
parum malaria without distinguishing between them, and one 
product was designed to detect P. vivax only. Manufacturers 
submitted two lots of each product for evaluation. When the 
same products (7) were resubmitted in subsequent rounds 
of testing, the second set of results replaced those from 
the earlier round. Thus, the performance of some tests in 
the results below differs from that reported in rounds 1–4.
Of the 22 products due for compulsory retesting in round 5, 
10 were submitted (Table S1). Round 1 products that were not 
1 See full reports of rounds 1–5 (3–6) for lists of collaborating partners. 
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resubmitted have been removed from the figures and tables 
in this summary performance document.
The aim of the evaluation is to provide comparative data 
on the performance of the submitted production lots of 
each product. These data will be used to guide procure-
ment decisions by WHO, other United Nations agencies 
and national governments and constitute the laboratory 
evaluation component of the WHO prequalification process 
for malaria RDTs (8). Product testing is part of a continuing 
programme of work to improve the quality of RDTs in use 
and to ensure reliable malaria diagnosis in areas where 
malaria is prevalent. A sixth round of product testing will 
begin in June 2014.
1.3. panel detection score and 
other results of the evaluation
The results (summarized in Figs S1–S3 and Tables S2 and S3) 
provide comparative data on two lots of products against a 
panel of parasite samples diluted to a low parasite density 
(200 parasites/µL) and a higher parasite density (2000 or 
5000 parasites/µL). The former is well below the mean 
parasite density found in many populations with endemic 
malaria and is considered close to the threshold that must 
be detected in order reliably to identify clinical malaria in 
many settings (9). For the purposes of this report, the main 
measure of performance is the panel detection score (PDS);1 
for each RDT evaluated, the PDS is measured separately at the 
1 Termed “detection rate” in the full report of round 1, published in 
2009. 
Box 1: Example calculation of panel detection score and positivity rate for product A against a sample density  
of 200 parasites/µL
The first reading was at the minimum time specified by the manufacturer; the second reading was up to 30 min latera. A sample is 























Test 1 Test 2
Detected if  
4 positive  
first readings
a second reading results are for internal use only
P. falciparum  
sample a b c d
1 + - + + Sample  NOT detected
2 + - - + Sample  NOT detected
3 + + + + Sample  detected
In this example, only one of three samples was positive all four times  
it was tested; the PDS is therefore 1/3 = 33%. 
The positivity rate is calculated as the percentage of all tests of a particular product that returned a positive test result at the 
manufacturers’ recommended minimum reading time when tested against a P. falciparum or P. vivax sample.
In the above example, the positivity rate is: 9/12 = 75%. 
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lower and the higher parasite density. The summary figures 
also show the false-positive rates against blood samples 
containing no malaria parasites or known markers of other 
diseases and the rate of invalid results. 
The PDS is the percentage of malaria samples in the panel 
that give a positive result in two RDTs per lot at the lower 
parasite density or by a single RDT per lot at the higher 
parasite density. As each sample is tested with RDTs from 
two lots, for a sample to be positive at the lower parasite 
density, it must show a positive result in four tests (two RDTs 
per lot for two lots); at the higher parasite density, it must 
show a positive result in two tests (one RDT per lot for two 
lots). Thus, the PDS is a combined measure of positivity rate, 
incorporating inter-test and inter-lot consistency. As all tests 
performed on each sample must show a positive result for 
the sample to be considered positive, the PDS for a given RDT 
will usually be lower than a simple positivity rate per panel, 
measured by comparing the number of positive tests among 
all tests performed per panel. The PDS is also different from 
clinical sensitivity: the ability of the test to detect malaria 
infection in a given population of infected patients. Boxes 1 
and 2 illustrate how the PDS is calculated and how it differs 
from a simple positivity rate for all samples tested and from 
clinical sensitivity in a population. 
The PDS for a given RDT is different from the clinical sensi-
tivity of that RDT (also called the true positive rate), which 
is a measure of the proportion of people known to have the 
disease who test positive for it. The sensitivity of malaria 
RDTs is highly dependent on local conditions, including the 
parasite density in the population; it therefore varies among 
populations with different levels of transmission, as their level 
of immunity affects the parasite density at which they exhibit 
symptoms that warrant a diagnostic test. Where transmission 
rates are low, the parasite densities in people with symptoms 
of malaria are likely to be low, and tests will be less sensitive. 
Test performance at 200 parasites/µL is therefore particularly 
important. The results in this report show the comparative 
performance of RDTs and indicate which products are likely 
to be more sensitive in the field, particularly in populations 
with low-density infections. 
In general, as countries reduce the prevalence of malaria 
and even move towards malaria elimination, detection of 
low parasite densities becomes increasingly important in 
case management. As the high PDS at 2000 parasites/µL 
indicates, the sensitivity of many of these products is similar 
in populations with higher parasite densities and therefore it is 
not possible to discriminate RDTs with superior performance.
Box 2: Performance measures in WHO product testing and in field settings: PDS versus clinical sensitivity
WHO Malaria RDT Product Testing
Primary performance measure: PDS indicates which 
products are likely to be more sensitive in the field, 
particularly in populations with low‐density infections.
200 parasites/μL
2000 parasites/μL
Reference panels: two fixed parasite densities allows 
discrimination in RDT performance. 
Malaria endemic setting
Performance measure: sensitivity is the proportion of the 
population studied who have malaria for whom the test is 
positive.
- high, moderate, low transmission
- immune, non-immune
- vulnerable groups
Patients have varying parasite density. Most RDTs for 
P. falciparum and P. vivax perform well for a parasite density 
> 2000 parasites/μL, but clinically significant densities 
< 200 parasites/μL may be missed. The “overall” test 
performance will nevertheless be classified as very good in a 
field evaluation. 
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An important caveat to estimating field sensitivity from the 
PDS provided in this report is that the panels used include 
only parasites known to express the target antigens. While 
non-expression of the target antigens has not been recorded 
for aldolase or pLDH, it is known that parasites that infect 
people in some areas of South America and India do not 
express HRP2 (10, 11). In areas where HRP2-deleted parasites 
exist, tests for HRP2 will have greatly reduced sensitivity or 
be incapable of detecting P. falciparum. In such populations, 
only tests for pLDH or aldolase in P. falciparum parasites will 
be effective for diagnosing falciparum malaria.
Heat stability (summarized in Table S3) is vital to maintaining 
the sensitivity of tests in the field. As a result, for procure-
ment, careful consideration must be given to ensure that 
the products to be used in areas with high temperatures 
of transport and storage have demonstrated stability in 
the product testing programme. Requirements vary among 
countries; for example, if tests are to be deployed in areas 
where temperatures rarely rise above 30 °C, less emphasis 
is needed on stability at high temperatures than on other 
aspects of quality. 
Ease-of-use requirements depend on the extent of training 
and the work environment of the users. Particularly in primary 
health care settings, the simpler the test, the easier it will be 
to avoid errors in preparation and interpretation.
Detailed results can be found in the report of each evalua-
tion (3–6) and at http://www.who.int/malaria/publications/
diagnostic_testing/en/. 
1.4. summary of outcomes
This laboratory-based evaluation provides a comparative, 
standardized measure of RDT performance for distinguishing 
between well and poorly performing tests to serve as a basis 
for procurement decisions by malaria control programmes 
and to guide United Nations procurement policy.
In round 5, the proportion of tests that achieved a PDS ≥ 75% 
at 200 parasites/µL is comparable to those in rounds 3 and 4 
for P. falciparum (78.6%); that for P. vivax, 42.4%, is similar 
to that in round 4.
Several RDTs in the five rounds of testing consistently detected 
malaria at a low parasite density (200 parasites/µL), had low 
false-positive rates, are stable at tropical temperatures, are 
relatively easy to use and can detect P. falciparum or P. vivax 
infections or both. 
Although the performance of the products varied widely 
at low parasite density (200 parasites/µL), all products 
had a high rate of detection of P. falciparum at 2000 or 
5000 parasites/µL, as did the majority of products for P. vivax 
at 2000 parasites/µL.
P. falciparum tests that target the HRP2 antigen had the 
highest detection rates, and two previously evaluated tests 
that target pan-pLDH for detection of Plasmodium spp. infec-
tion also achieved a good PDS. In round 5, the two poorest 
performing tests for detection of P. falciparum were based 
on P. falciparum-specific pLDH detection. Thus, the choice 
of well-performing pLDH-based P. falciparum tests remains 
limited, as it does for pan-only-specific tests. 
Test performance sometimes varied between lots and widely 
between similar products, confirming the advisability of 
testing lots after purchase and before use in the field. 
Furthermore, anomalies that interfered with test interpreta-
tion were regularly recorded during round 5 (Annex S2). All 
products had issues with red background and with incomplete 
clearing, and cases of samples failing to flow or migrate on 
the RDT were reported for 62% of products. 
Ninety-eight percent of the RDTs evaluated in round 5 were 
in cassette format. 
With regard to products retested under the compulsory 
resubmission requirement, one showed improved (4.8%) 
detection of P. falciparum and one improved (4.3%) detection 
of P. vivax, while six and two had diminished performance 
(> 5% decrease) for detection of P. falciparum (mean, 13.9%; 
median, 8.4%) and P. vivax (mean, 8.5%), respectively. All 
products except one had the same or lower false-positive 
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1.5. How can product testing 
results inform rdt procurement 
and use?
Accurate diagnosis is vital to good malaria case management, 
whether based on microscopy or RDTs. The results of this 
report should be used to identify a short list of RDTs for 
procurement for use in settings where good microscopy is not 
available or appropriate. Box 3 lists WHO’s minimum criteria 
for RDT selection, and Annex S3 provides a step-by-step 
approach to selecting an RDT, taking into consideration local 
malaria transmission and illness where the tests will be used 
(e.g. Plasmodium species, target antigen, parasite densities, 
climate) and other important considerations, including ease 
of use in the field (Annex S2), training or retraining require-
ments and lot testing.1
The tabular results in TableS2 are colour-coded to reflect 
achievement of WHO performance requirements for RDT 
procurement, and a web-based tool that allows filtering of 
product testing results by various parameters to assist in 
selecting products with the performance characteristics most 
suitable for a country’s health programme is available and 
maintained by FIND (12). Comprehensive guidance on several 
aspects of procurement can be found in Good practices for 
selecting and procuring rapid diagnostic tests for malaria and 
guidance on implementation in Universal access to malaria 
diagnosis (13, 14).
1 The WHO-FIND malaria RDT evaluation programme provides lot-
testing capacity in two regional laboratories free of charge; it can 
be accessed at malaria_rdt@who.int and info@finddiagnostics.org. 
1.6. product testing and WHo 
programme for prequalification of 
diagnostics and medical devices
The WHO prequalification of diagnostics and medical devices 
programme uses the results of product testing as the labora-
tory evaluation component of the prequalification process 
for malaria RDTs. These data are used to set priorities for 
dossier review and inspection. Although prequalification is 
not currently a requirement for WHO procurement, manu-
facturers are encouraged to apply for it. A list of prequalified 
diagnostics, including malaria RDTs, is available at http://
www.who.int/diagnostics_laboratory/evaluations/PQ_list/en/.
Box 3: WHO selection criteria for the procurement of RDTs
Products should be selected in line with the following set of criteria, based on the results of the assessment of the WHO Malaria 
RDT Product Testing Programme:
(A) For the detection of Plasmodium falciparum (Pf) in all transmission settings the panel detection score (PDS) against Pf 
samples should be at least 75% at 200 parasites/μL.
(B) For the detection of Plasmodium vivax (Pv) in all transmission settings the panel detection score (PDS) against Pv samples 
should be at least 75% at 200 parasites/μL.
(C) The false positive rate should be less than 10%.
(D) The invalid rate should be less than 5%.
Only products meeting performance criteria outlined in A,B,C and D are recommended for procurement
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Figure S1: Malaria RDT performance in phase 2 of rounds 2-5 against wild-type (clinical) samples containing P. falciparum  
at low (200) and high (2000-5000) parasite density (parasites/μL) and clean-negative samples
a Panel detection score: A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive. 
b Clean-negative, blood samples from healthy volunteers with no known current illness or blood abnormality. 
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Figure S1: Malaria RDT performance in phase 2 of rounds 2-5 against wild-type (clinical) samples containing P. falciparum  
at low (200) and high (2000-5000) parasite density (parasites/μL) and clean-negative samples
a Panel detection score: A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive. 
b Clean-negative, blood samples from healthy volunteers with no known current illness or blood abnormality. 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































False-positive Plasmodium spp. rate (%)
Invalid rate (%)
8 Malaria rapid diagnostic test perforMance – summary results of WHo product testing of malaria rdts: round 1-5 (2008-2013)
Figure S2: Malaria RDT performance in phase 2 of rounds 2-5 against wild-type (clinical) samples containing  
P. vivax at low (200) and high (2000 or 5000) parasite density (parasites/μL) and clean-negative samples
a Panel detection score - A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive. 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































98 Malaria rapid diagnostic test perforMance – summary results of WHo product testing of malaria rdts: round 1-5 (2008-2013)
Figure S2: Malaria RDT performance in phase 2 of rounds 2-5 against wild-type (clinical) samples containing  
P. vivax at low (200) and high (2000 or 5000) parasite density (parasites/μL) and clean-negative samples
a Panel detection score - A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive. 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































False-positive Plasmodium spp. rate (%)
Invalid rate (%)
10 Malaria rapid diagnostic test perforMance – summary results of WHo product testing of malaria rdts: round 1-5 (2008-2013)
Figure S3: Panel detection score of malaria combination and pan-only RDTs, meeting WHO procurement criteria for 
false-positive and invalid rates, in phase 2 of rounds 2-5 against wild-type (clinical) samples containing P. falciparum 
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1 diagnosticks MALARIA (Pan/Pf) Cassette- MPNFWBC1007.4
2 Core™ Malaria Pv/Pf - MAL-190022
3 FalciVax™ - Rapid test for Malaria Pv/Pf - 50300025
4 SD BIOLINE Malaria Ag Pf/ Pf/ Pv - 05FK100
5 SD BIOLINE Malaria Ag Pf/Pv - 05FK80/05FK83
6 Malaria pf (HRP II) / (PAN-pLDH) Antigen Detection Test Device - MFV-124R
7 IND ONE STEP MALARIA ANTIGEN P.f/Pan TEST - 535-10
8 SD BIOLINE Malaria Ag P.f/Pan - 05FK60/05FK63
9 BIONOTE MALARIA P.f.& Pan Ag Rapid Test Kit - RG19-08
10 diagnosticks MALARIA (Pan/Pv/Pf) Cassette - MPNVFC1007.5
11 ICT Malaria Dual Test - ML03
12 BIONOTE MALARIA P.f.& P.v. Ag Rapid Test Kit - RG19-12
13 Core™ Malaria Pan/Pv/Pf - MAL-190026
14 NanoSign Malaria pf/pan Ag 3.0 - RMAP10
15 Humasis Malaria P.f/P.v Antigen Test - AMFV-7025
16 RAPID 1-2-3® HEMA CASSETTE MALARIA PF/PV TEST - MAL-PFV-CAS/25(100)
17 Parascreen® - Rapid test for Malaria Pan/Pf - 50310025
18 OnSight™ - ParaQuick-2 (Pv,Pf) Malaria Test - 537-25-DB
19 diagnosticks- Malaria (Pv/Pf) Cassette - KMVFC6002
20 CareStart™ Malaria HRP2/pLDH (Pf/Pv) COMBO - G0161
21 Medisensor Malaria HRP2/pLDH (Pf/Pv) COMBO - M161
22 SD BIOLINE Malaria Ag Pf/ Pan - 05FK66
23 CareStart™ Malaria HRP2/pLDH (Pf/PAN) COMBO - G0131
24 DIAQUICK Malaria P.f/Pan Cassette - Z11200CE
25 Humasis Malaria P.f/Pan Antigen Test - AMAL-7025
26 CareStart™ Malaria HRP2/pLDH (Pf/VOM) COMBO - G0171
27 HiSens Malaria Ag P.f/P.v Combo Card - HR3123
28 HiSens Malaria Ag P.f/VOM Combo Card - HR3323
29 Medisensor Malaria HRP2/pLDH (Pf/VOM) COMBO - M171
30 Malaria Pf/Pan One Step Rapid Test - RT 20222
31 CareStart™ Malaria pLDH 3 Line Test - G0121
32 Advanced Quality™ Rapid Malaria Test (Pf/Pan) - ITP11005
33 FirstSign™ ParaView (Pan+Pf) - 2101CB-25
34 Wondfo® One Step Malaria P.f/P.v Whole Blood Test - W056-C
35 CareStart™ Malaria Screen - G0231
36 OnSite Pf/Pan Ag Rapid Test - R0113C
37 Vikia® Malaria Ag Pf/Pan - 412499
38 ABON™ Plus Malaria P.f/Pan Rapid Test Device (Whole Blood) - IMA-T402
39 First Response® Malaria Ag. pLDH/HRP2 Combo Card Test - I16FRC
40 Malaria Pf (HRPII)/ PV (PLDH) Antigen Detection Test Device - GM006
41 ParaHIT - Total Ver. 1.0 (Device) - 55IC204-10
42 Advantage Malaria Pan + Pf Card - IR231025
43 GenBody™Malaria Pf/Pan Ag - MALAG100
44 HiSens Malaria Ag Pf/Pv (HRP2/pLDH) Card - HR2923
45 Maleriscan® Malaria Pf/PAN (Pv, Pm, Po) 3 Line Antigen Test - MAT-PF/PAN-50
46 CareStart™ Malaria/Pregnancy Combo (pLDH/HRP2/HCG) - G0221
47 Surestep™ Easy Malaria Pf/Pan Rapid Test Device - IMA-T402
48 EzDx™ Malaria Pan/Pf Rapid Test Detection kit - RK MAL 001
49 Clearview® Malaria Combo - VB11
50 Malascan™ Device - Rapid test for Malaria Pf/Pan - 50402025
51 ASAN Easy Test® Malaria Pf/Pan Ag - AM4650-K
52 Malaria pf (HRP II) / pv (pLDH) Antigen Detection Test Device - MFV-124V
53 OnSite Pf/Pv Ag Rapid Test - R0112C
54 Advantage Malaria Card - IR211025
55 BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH) - C30RHA25
56 BioTracer™ Malaria Pf/PAN Rapid Card - 17012
57 ICT MALARIA COMBO - ML02
58 ParaHIT - Total Ver. 1.0 (Dipstick) - 55IC203-10
59 IMMUNOQUICK CONTACT MALARIA +4 - 0525K25
60 ABON Malaria Pan/P.f. Rapid Test Device - IMA-B402
61 MeDiPro Malaria Ag HRP2/pLDH Combo - IR-0051K
62 ACCUCARE ONE STEP MALARIA Pf/Pan Antigen Test - MAGC 25
63 ParaHIT® total (dipstick) - 55IC201-10
64 Malaria pf (HRP II)/PAN (pLDH) Antigen Detection Test Device - 1-13-101-1
65 ParaHIT®fV Rapid test for P. falciparum and P.vivax Malaria - Device - 55IC402-5
66 AZOG Malaria pf (HRPII)/pf (LDH)/ (PAN-LDH) Antigen Detection Device - MFV-124F
67 Malaria Pf./Pan Antigen (MAL Pf/Pan) Test Kit - A03-18-322
68 Malaria pf (HRP II) / pv (pLDH) Antigen Detection Test Device - MFV-124V
69 Maleriscan® Malaria Pf/Pv - MAT-50
70 OptiMAL-IT - 710024
71 Malaria Pf/Pv - GM002
72 Malaria Pf/ PAN - GM004
73 One Step Malaria P.f/Pan Test - W56-C
74 Advantage Mal Card - IR221025
75 HiSens Malaria Ag P.f/P.v Card - HR2823
76 SD BIOLINE Malaria Ag - 05FK40
77 NanoSign Malaria Pf/Pv Ag - RMAD10















1110 Malaria rapid diagnostic test perforMance – summary results of WHo product testing of malaria rdts: round 1-5 (2008-2013)
Table S1: Product resubmissions: WHO malaria RDT product testing rounds 1—5





CareStart™ Malaria HRP2/PLDH (Pf/Pv) COMBO G0161 2, 4
CareStart™ Malaria HRP2/PLDH (Pf/VOM) COMBO G0171 2, 4
CareStart™Malaria HRP2 (Pf) G0141 1 5
CareStart™ Malaria HRP2/pLDH (Pf/PAN) Combo G0131 1 5
CareStart™Malaria pLDH (PAN) G0111 1 5
Advy Chemical Pvt. Ltd. (Affiliate of 
Bharat Serums & Vaccines Ltd. ) EzDx™ Malaria Pan/Pf Rapid Test Detection Kit RK MAL 001 4, 5
Biosynex IMMUNOQUICK® MALARIA falciparum 0502_K25 1 5
AZOG
Malaria pf (HRP II) / (PAN-LDH) Antigen Detection Test Devicea MFV-124R 1, 3
Malaria pf (pLDH) / PAN-pLDH Test Device MFV-124 3, 5
Bhat Bio-Tech India (P) Ltd. Maleriscan® Malaria Pf/PAN (Pv, Pm, Po) 3 Line Antigen Test MAT-PF/PAN-50 4, 5
Bioland NanoSign Malaria Pf/Pan Ag RMAP10 3, 4
Blue Cross Bio-Medical (Beijing) Co., Ltd.
One Step Malaria Pf Test (cassette) 522352 2, 3, 4
One Step Malaria P.F/P.V Test (Cassette) 523352 4, 5
CTK Biotech, Inc.
Onsite Pf Ag Rapid Test R0114C 2, 3
Onsite Malaria Pf/Pan Malaria Ag Rapid Test R0113C 2, 3, 4, 5
Onsite Malaria Pf/Pv Ag Rapid Test R0112C 2, 3, 4
DiaMed - A Division of Bio-Rad OptiMAL-IT 710024 1, 3
Guangzhou Wondfo Biotech Co. Ltd.
Wondfo One Step Malaria Pf/Pan Whole Blood Test W56-C 1, 3
One Step Malaria P.f Testb W37-C 2, 3, 4
ICT INTERNATIONAL
ICT Malaria Combo Cassette Test ML02 1, 3, 4
ICT Malaria Pf Cassette Test ML01 1, 3
ICT Malaria Dual Test ML03 3, 5
InTec Products, Inc.  Advanced Quality™ One Step Malaria Pf Test ITP11002TC1/TC40 1, 3 5
Humasis Co., Ltd. Humasis Malaria Pf/Pan Antigen Test AMAL-7025 4, 5
J.Mitra & Co. Pvt. Ltd.
Advantage Pan Malaria Card IR013025 1 5
Advantage Mal Card IR221025 1 5
Advantage P.f Malaria Card IR016025 1 5
Orchid Biomedical Systems
Paracheck® Pf Device - Rapid test for P. falciparum Malaria (Ver. 3)c 30301025 1, 3, 4
Paracheck® Pf Dipstick - Rapid test for P. falciparum Malaria (Ver.3)c 30302025 1, 3, 4
Premier Medical Corporation Ltd. 
First Response® Malaria Ag Combo (pLDH/HRP2)d I16FRC 1, 2, 5
First Response Malaria Ag P. falciparum (HRP2) Card Test I13FRC 1 5
SSA Diagnostics & Biotech Systems diagnosticks- Malaria (Pf)Cassette WB KMFC6001 2, 5
Standard Diagnostics Inc. 
SD BIOLINE Malaria Ag  05FK40 1, 3
SD BIOLINE Malaria Ag Pf/Pan 05FK60/05FK63 1, 3, 5
SD BIOLINE Malaria Antigen 05FK50/05FK53 1 5
Unimed International Inc. FirstSign™ - ParaView (Pan+Pf) Malaria Test 2101 CB-25 2, 4
Vision Biotech (Pty) Ltd / Orgenics (Alere 
Healthcare (Pty) Ltd subsidaries)
Malaria Rapid Combo/Clearview® Malaria Combo VB11e 1, 3
Malaria Rapid Pf /Clearview ®Malaria Pf VB01 1, 3, 5
Malaria Rapid Dual/Clearview® Malaria Dual Test Device VB20e 1, 3, 5
Zephyr Biomedical Systems
Malascan™ Device - Rapid test for Malaria Pf/Pan 50402025 1, 3
Parabank™ Device - Rapid test for Malaria Pan 50301025 1, 3
Parascreen™ Device -Rapid test for Malaria Pan/Pf 50310025 1, 3, 4, 5
Falcivax Rapid Test for Malaria Pv/Pf (device) 50300025 2, 4
a Round 1 product name error: published - Malaria Pf (HRPII)/pv-LDH) Antigen Detection Test Device Code; corrected product name: Malaria Pf (HRPII/PAN-LDH) Antigen 
Detection Test Device Code. No change in product code.
b In round 2, product did not pass phase-1, therefore results do not feature in summary tables. 
c Ver.3 was introduced after round 1
d Error in WHO malaria RDT product testing: round 1 report: product code (II6FRC30) should have been ( I16FRC ), as in round 2
e New company acquisition (Alere™), therefore change in product branding and catalogue numbers; VB011 to VB11 and VB020 to VB20. Manufacturer confirmed 
compliance with product definition. 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































20 Malaria rapid diagnostic test perforMance – summary results of WHo product testing of malaria rdts: round 1-5 (2008-2013)
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2120 Malaria rapid diagnostic test perforMance – summary results of WHo product testing of malaria rdts: round 1-5 (2008-2013)
annexes
22 Malaria rapid diagnostic test perforMance – summary results of WHo product testing of malaria rdts: round 1-5 (2008-2013)
annex s1: characteristics of 
evaluation panels used in rounds 
1–5 of WHo malaria rdt product 
testing, 2008–2013
Currently, the basis for diagnosing malaria with antigen-
detecting RDTs is the detection in a patient’s blood of one or 
more target malaria antigens, including HRP2 (P. falciparum 
only), pLDH (Plasmodium spp.(pan-pLDH), P. falciparum 
(Pf-pLDH), non-falciparum (Pv-pLDH, Pvom-pLDH) and 
aldolase (all Plasmodium spp). The antigen concentration in 
samples with the same parasite density varies. Therefore, 
the concentrations of malaria antigens in the samples that 
comprise evaluation panels must be consistent in successive 
rounds of WHO malaria RDT product testing to ensure that 
the results of each round are highly comparable (statistically 
equivalent). 
Therefore, antigen concentrations were quantified in triplicate 
in all panel samples, including dilution pairs of 200 and 
2000 parasites/µL, by quantitative ELISA. Only results that 
were consistent in the triplicate runs and showed a value 
factor between the 200 and the 2000 parasites/µL dilutions 
close to 10 were considered acceptable and eligible for the 
performance evaluation panel. In some instances, the antigen 
concentration was below the detection limit of the ELISA, 
particularly for aldolase, which is present in malaria parasite 
samples at much lower concentrations than the other two 
antigens. Samples that gave inconsistent results for more 
than one of the three antigens were excluded from the panel.
Despite careful standardization of procedures, the tables and 
figures below show a wide variation in antigen concentra-
tions for the same parasite density. There are a number of 
possible explanations, including differences in the level of 
antigen expression by isolates; different durations of infection 
(accumulating antigens); different parasite growth stages at 
the time of collection (expressing different levels of antigen); 
the presence of circulating HRP2 from previous growth 
cycles; and HRP2 produced by parasites sequestered in the 
host’s vascular tissues that cannot be accounted for in the 
estimate of parasite density on the blood slide.
Before each round of WHO malaria RDT product testing,  the 
distribution of HRP2, pLDH and aldolase concentrations at 
200 parasites/µL dilution of the wild-type P. falciparum and 
wild-type P. vivax samples selected for the phase-2 panels 
were systematically compared with those in the previous 
round to ensure there was no statistically significant differ-
ence. The figures and tables below show the distribution of 
antigen concentrations in all five performance evaluation 
panels. No statistically significant differences were seen 
(Kruskal-Wallis test; p > 0.15), confirming that the results 
of each new round are additive (and comparable) to the 
previous ones. In the following box and whisker plots, the 
end of whiskers represent minimum and maximum values; 
the box represents middle 50% of data and the line through 
box represents median values; the crosses represent the 
mean values.
Figure AS1.1: Box-and-whisker plot of distribution of 
P. falciparum HRP2 concentration (ng/mL) in product 
testing phase 2 (wildtype) panels.
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Figure AS1.3: Box-and-whisker plot of distribution of 
P. vivax pLDH concentration (ng/mL) in product testing 
phase 2 (wild-type) panels.
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Figure AS1.2: Box-and-whisker plot of distribution of 
P. falciparum pLDH concentration (ng/mL) in product 
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Figure AS1.4: Box-and-whisker plot of distribution of 
P. falciparum aldolase concentration (ng/mL) in product 
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Figure AS1.5: Box-and-whisker plot of distribution 
of P. vivax aldolase concentration (ng/mL) in product 
testing phase 2 (wild-type) panels.
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Table AS1.1: Statistics for P. falciparum HRP2 concentration (ng/mL) in product testing phase 2 (wild-type) panels.   
Round 1 Round 2 Round 3 Round 4 Round 5
Number of valuesa 78 99 99 98 99
Minimum 0.80 0.62 0.62 0.62 0.62
25% percentile 2.90 1.90 2.10 2.97 3.00
Median 9.57 6.76 6.83 6.98 7.05
75% percentile 18.94 16.91 17.37 15.65 15.31
Maximum 73.70 73.70 66.70 62.48 62.48
Mean 15.28 12.70 12.77 12.72 11.74
Std. Deviation 16.98 15.75 15.19 14.72 13.20
a The number of values is the number of samples for which consistent ELISA results were obtained.
Table AS1.2: Statistics for P. falciparum pLDH concentration (ng/mL) in product testing phase 2 (wild-type) panels.   
Round 1 Round 2 Round 3 Round 4 Round 5
Number of valuesa 74 93 92 92 94
Minimum 0.71 0.19 0.19 0.19 0.19
25% percentile 6.68 6.27 6.23 6.20 6.90
Median 11.95 10.31 11.18 10.92 12.24
75% percentile 23.75 20.10 22.70 21.28 23.05
Maximum 47.15 47.15 47.15 53.53 43.02
Mean 15.31 13.71 15.08 14.97 15.53
Std. Deviation 11.47 10.90 11.72 11.98 11.43
a The number of values is the number of samples for which consistent ELISA results were obtained.
Table AS1.3: Statistics for P. vivax pLDH concentration (ng/mL) in wildtype product testing phase 2 (wild-type) panels. 
Round 1 Round 2 Round 3 Round 4 Round 5
Number of valuesa 20 37 33 32 34
Minimum 5.10 1.64 1.64 1.64 1.64
25% percentile 8.10 8.40 7.30 6.96 6.26
Median 12.65 17.00 19.78 17.50 13.22
75% percentile 27.40 29.69 31.89 29.84 23.42
Maximum 44.40 47.90 47.90 47.90 47.90
Mean 17.38 20.24 20.99 20.00 16.84
Std. Deviation 11.57 13.27 13.55 13.00 12.59
a The number of values is the number of samples for which consistent ELISA results were obtained.
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Table AS1.4: Statistics for P. falciparum aldolase concentration (ng/mL) in product testing phase 2 (wild-type) panels. 
Round 1 Round 2 Round 3 Round 4 Round 5
Number of valuesa 77 98 99 98 99
Minimum 0.00 0.00 0.00 0.00 0.00
25% percentile 0.84 0.74 0.67 0.63 0.52
Median 1.61 1.49 1.40 1.25 1.17
75% percentile 2.25 2.25 2.23 2.25 2.07
Maximum 9.90 9.90 9.90 9.08 7.74
Mean 1.93 1.79 1.76 1.72 1.52
Std. Deviation 1.73 1.66 1.69 1.68 1.52
a The number of values is the number of samples for which consistent ELISA results were obtained.
Table AS1.5: Statistics for P. vivax aldolase concentration (ng/mL) in product testing phase 2 (wild-type) panels. 
Round 1 Round 2 Round 3 Round 4 Round 5
Number of valuesa 20 40 34 33 35
Minimum 3.21 1.70 1.70 1.70 3.21
25% Percentile 4.02 4.11 4.07 4.41 5.55
Median 6.33 6.15 6.10 6.16 6.86
75% Percentile 8.47 8.47 8.32 9.10 9.43
Maximum 13.15 13.40 13.30 15.00 15.00
Mean 6.73 6.81 6.45 6.86 7.78
Std. Deviation 2.89 3.15 2.90 3.23 3.30
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annex s2: Malaria rdt field assessment and anomalies
The purpose of this assessment, on a limited number of RDTs, is to assess aspects of packaging, safety and ease-of-use and 
not to evaluate diagnostic accuracy.  
Obtain samples of each malaria RDT under consideration (at least one box packaged as intended for delivery to end users).
Obtain malaria parasite-negative blood samples, and where readily accessible, parasite-positive blood samples for testing 
against RDTs. 
Table AS2.1: Field assessment of RDT packaging, safety and ease-of-use to guide product selection 




Yes No NA Problems /Comments
Packaging and accessories
The RDT box is in good condition
RDTs are in individual sealed pouches
The correctly indicated number of RDTs are in the box
A desiccant is included in each individual RDT pouch 
An expiry date is visible on each RDT pouch
All required accessories are included in the correct quantities 
(RDT, buffer, blood transfer device, alcohol swab, 
lancet, gloves, test tubes (for dipsticks, only) 
If no, what is not included: 
Instructions
Instructions are included 
Instructions are in the national language(s)
The instructions are for the correct product 
The instructions include figures displaying 
all possible interpretations of the RDT results
The text and figures are accurate and consistent 
(specifically order of test lines and results interpretation)
Preparation and procedure
The test pouch is easy to open
It is easy to write on the test device 
The test lines on the device are clearly labelled
It is easy to use the device for blood collection
It is easy to open the buffer bottle or ampoule
The buffer bottle or ampoules have sufficient volume 
for testing all RDTs in the box
The buffer bottle or ampoule dispenses even drops
It is easy to fill the sample well correctly with the provided blood 
transfer device
It is easy to fill the buffer well correctly (no overflow)
The buffer and sample flow well along the test strip 
Result interpretation
Control and test lines 
Control line is clear
Test line(s) are clear
Good clearance of blood by time of reading If no, number of tests in the box affected: 
Steps and reading time 
Reading time <30 min
Two or fewer timed steps 
Was one or more of the last 10 tests 
you performed invalid (no control line)?
If YES, how many?
Safety
Are there mixing wells (risk of blood splash)?
Retractable needle for finger prick?
Is the RDT in a cassette format (unexposed strip)?
Have waste disposal safety concerns been addressed? 
(If no, please describe)
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Figure AS2.1 illustrates examples of RDT observations/anomalies encountered and routinely recorded during Round 5 of 
WHO Malaria RDT Product Testing at the CDC. In most cases, these anomalies do not invalidate the results, as reactivity 
in the control and test line areas are still visible, but they may pose challenges to health workers interpreting the results. 
Furthermore, they should be reported to manufacturers. 
An expanded list of notable observations concerning RDT packaging, kit accessories (buffer vials, desiccants) and instruc-
tions for use, is under development for use in both product testing and lot testing activities of the WHO-FIND Malaria RDT 
Evaluation Programme. 
Figure AS2.1: Malaria RDT anomalies encountered in production lots 
a) Observations on the test strip
Red background Background staining is relatively common. 
In this example, the result is positive as test 
lines are positive; however, a more intense 
red background may obscure weak positive 
test lines, giving false-negative results
Incomplete clearing Poor clearing of blood may obscure weak 
positive test lines, giving false-negative 
results. 
In this example, the result is positive as 
the test line is visible
b) Observations of flow problems
Failure to flow Blood and buffer did not run the length 
of the strip
Irregular migration that 
obscures test line(s)
One portion of the nitrocellulose near the 
test band was not absorptive and remained 
dry during wicking, creating irregular migra-
tion of blood/buffer with red background 
that may obscure test line.
Irregular migration One portion of the nitrocellulose near the 
test band was not absorptive and remained 
dry during wicking, creating irregular migra-
tion of blood/buffer with red background. 
In this example, the result is positive, as the 
test line is clearly visible.
C  T1 T2
C  T
C  T1  T2
C  T
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c) Observations on test lines
Ghost test lines White lines on a stained background. In this 
example, the result is negative, as the test 
line is not dark and is thus not visible.
Patchy broken test 
line(s)
The test line is visible but interrupted 
(broken). 
Diffuse test line(s) Test line wider than control, without 
clearly defined edge. 
d) RDT structural problems
Strip misplaced in the 
cassette
Strip can be seen only partially in the 
results window.
Specimen pad not seen 
in sample window
Normally, the colour of the conjugated 
antibody can be seen in the sample 
window (commonly purple, pink or blue). 
C   T1  T2  T3
C   T1  T2
C  T
C    T1  T2

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Figure AS3.1: How to select of an appropriate RDT
Step 1.1
Define setting of use
What? target parasite species and antigena




Pf and non-Pf infections (single species)b:
- HRP2, aldolase; HRP2, pLDH-pan
- HRP2, pLDH-Pv; HRP2, pLDH-Pvom
- HRP2, pLDH-pan; pLDH-Pv






**Pf without HRP2 – Do not use HRP2-based RDTsc
Where? Exposure to high temperature e.g. tropical environment 
                      OR
temperature-controlled environment, including during 
transport and storage
Who? Laboratory personnel
           OR




WHO RDT product testing resultsd and apply WHO recommended RDT selection 
criteriae
- Panel detection score 
- False-positivity rate 
- Invalid rate 
- Ease-of-use
- Thermal stability
Sensitivity and specificity based on high-quality 
field studies in relevant populations 
Generate short-list of RDTs
Step 1.3
Apply national guidelines  
and experience in use of RDTs 
National malaria treatment guidelines
In-country experience, ease-of-use assessments (Annex 5),  




- Manufacturer: production capacity, lead times, heat stability data
- Delivery schedules (e.g. staggered deliveries), box size, shelf life
- Registration requirements of national regulatory authorities
- Product lot testing results
- Overall budget requirements (Annex 5)
a Pf-only or mixed Pf/non-Pf infections: Most areas of sub-Saharan Africa and lowland Papua New Guinea; Pf and non-Pf infections (single species): Most endemic areas of 
Asia and the Americas and isolated areas of the Horn of Africa; Mainly P. vivax-only: areas of East Asia, central Asia, South America, and some highland areas elsewhere
b Tests with a P. falciparum-specific line and pan-specific line will not distinguish P. falciparum-only infections from mixed P. falciparum infections. Distinguishing 
P. falciparum from mixed P. falciparum-vivax infections is important only if a full course of primaquine is routinely given for infections due to P. vivax. This must 
be weighed against the loss of ability to detect P. malariae and P. ovale if a test has only P. falciparum- and P. vivax-specific lines. Inclusion of further test lines 
(e.g. Pf-Pv-pan-pLDH) to detect these increases the complexity of test interpretation. A programme should prioritize these various advantages and disadvantages 
according to local conditions in the initial stage of making procurement decisions.
c  P. falciparum parasites lacking HRP2 +/- HRP3 genes have been identified with high frequency in parts of South America (10). 
d See references (3–6).
e WHO RDT procurement criteria : http://www.who.int/malaria/publications/atoz/rdt_selection_criteria/en/ (accessed 26 June 2014).
For a comprehensive guide to procurement of malaria RDTs extending beyond selection to  quantification, budgeting, 
technical specifications, management of tenders, contracts, supply management and monitoring of supplier performance 
and managing product variations, see reference (13).
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